NeuroBo Q2 net loss narrows to $0.7M; DA-1241 Phase 2a dosing expected Sept 2023

MetaVia Inc.

2023-Q2 EPS reported -$0.08

Net loss of $0.7M ($0.02/share) in Q2 2023 vs $3.3M in Q2 2022; cash $28.7M sufficient into 2024.
First patient dosing in Phase 2a trial of DA-1241 for NASH expected September 2023.
Signed term sheet with MThera to out-license NB-01 for painful diabetic neuropathy worldwide except Korea.
Preclinical data for DA-1726 shows superior weight loss vs semaglutide and tirzepatide; IND submission expected H2 2023.
R&D expenses increased to $2.4M from $1.0M YoY, driven by DA-1241 preparation.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

MetaVia Inc. reported financial results for the second quarter ended June 30, 2023.

Period: the second quarter ended June 30, 2023
Result: reported results

Exact text from the filing

NeuroBo Pharmaceuticals, Inc. (the “Company” ) issued a press release announcing its financial results for the second quarter ended June 30, 2023

View on SEC.gov

23 earnings releases filed in the last 30 days. Browse all earnings releases →

MetaVia Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-014281

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.